イリノイ州における鎌状赤血球症の臨床試験
イリノイ州内の拠点で、鎌状赤血球症に関する19件の研究が参加者を募集しています。
イリノイ州内の都市
公式研究テキスト（英語）
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
- University of Illinois at Chicago College of Medicine, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04055818A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Uni of Illinois Hospital and HSC, Chicago
被験者募集中第3相
12歳〜100歳 · 全性別 · 2026/09/28更新 · NCT06439082A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- University of Illinois Hospital and Health Sciences System, Chicago
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07187973A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Univer Of Illinois at Chicago, Chicago
被験者募集中第3相
2歳以上 · 全性別 · 2026/09/18更新 · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Childrens Hospital of Chicago, Chicago
- Univer Of Illinois at Chicago, Chicago
被験者募集中第3相
12歳以上 · 全性別 · 2026/09/17更新 · NCT06612268Tocilizumab for Acute Chest Syndrome
- University of Chicago, Chicago
被験者募集中第2相
12歳以上 · 全性別 · 2026/09/15更新 · NCT05640271A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Local Institution - 0034, Chicago
被験者募集中第1/2相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/08/18更新 · NCT06481306A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD
- University of Illinois at Chicago Clinical Research Center, Chicago
- University of Illinois Hospital and Health Sciences System - Investigational Drug Services (IDS), Chicago
- University of Illinois Hospital and Health Sciences System, Chicago
被験者募集中第2/3相
12歳以上 · 全性別 · 2026/08/18更新 · NCT05431088ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Rush University Medical Center, Chicago
- Bleeding and Clotting Disorders Institute, Peoria
被験者募集中観察研究
全年齢 · 全性別 · 2026/08/17更新 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Illinois at Chicago, Chicago
被験者募集中第2相
12歳以上 · 全性別 · 2026/08/14更新 · NCT06699849The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- University of Illinois-Chicago - College of Medicine- Site Number : 8400054, Chicago
被験者募集中第3相
10歳〜65歳 · 全性別 · 2026/07/29更新 · NCT06975865Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease
- University of Illinois at Chicago, Chicago
被験者募集中第2相
16歳〜60歳 · 全性別 · 2026/07/08更新 · NCT03121001Sickle Cell Clinical Research and Intervention Program
- Children's Hospital of Illinois at OSF-Saint Francis Medical Center, Peoria
被験者募集中観察研究
全年齢 · 全性別 · 2026/06/04更新 · NCT02098863Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Comer Children's Hospital (MRD-HCT), Chicago
被験者募集中観察研究
3歳〜20歳 · 全性別 · 2026/06/04更新 · NCT06941389Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using the SGLT2 Inhibitors, Empagliflozin
- University of Illinois Chicago, Sickle Cell Center, Chicago
被験者募集中第2相
18歳〜60歳 · 全性別 · 2026/05/19更新 · NCT07175051Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- University of Illinois at Chicago, Chicago
被験者募集中
18歳以上 · 全性別 · 2026/03/23更新 · NCT06919224Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中第2相
2歳〜25歳 · 全性別 · 2026/03/10更新 · NCT03587272Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
- Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago
被験者募集中
16歳〜30歳 · 全性別 · 2026/01/07更新 · NCT06374238Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Illinois, Chicago
被験者募集中観察研究
18歳以上 · 全性別 · 2025/06/22更新 · NCT06385886ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。